Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF’s Spring Clinical Meetings

Ardelyx (Nasdaq: ARDX) announced an abstract accepted for a poster at the National Kidney Foundation Spring Clinical Meetings, May 7-10, 2026, in New Orleans.

Rhea-AI Summary

Ardelyx (Nasdaq: ARDX) announced an abstract accepted for a poster at the National Kidney Foundation Spring Clinical Meetings, May 7-10, 2026, in New Orleans. The poster reports long-term effects of XPHOZAH (tenapanor) on serum electrolytes and select nutrition biomarkers in dialysis patients with hyperphosphatemia.

The poster (G-353) will display May 7, 2026, 5:15-7:30 PM CT, and Ardelyx will sponsor a Peer Exchange on May 8 reviewing XPHOZAH mechanism, efficacy, safety, and practical considerations for add-on therapy.

Argus Apr 27 session

+0.67% close to close Open Argus

Details

News Market Reaction – ARDX

On Apr 27, the day this news came out, ARDX closed 0.67% above the previous close.

Data tracked by StockTitan Argus for the Apr 27 session.

Key Figures

NKF meeting dates: May 7-10, 2026 Poster display time: 5:15–7:30 PM CT Peer exchange time: 12:15 PM CT +1 more

NKF meeting dates

May 7-10, 2026

National Kidney Foundation Spring Clinical Meetings in New Orleans

Poster display time

5:15–7:30 PM CT

Poster G-353 on May 7, 2026 at NKF Spring Clinical Meetings

Peer exchange time

12:15 PM CT

XPHOZAH-focused Peer Exchange on May 8 at NKF meetings

Dosing regimen

Single tablet twice daily

XPHOZAH administration schedule as add-on therapy for CKD patients on dialysis

Historical Context

5 past events · Latest: Apr 23

5 events

1. Apr 23

   Conference abstract

   24h Move

   -1.0%

   IBS-C treatment patterns poster and product theater at DDW 2026 announced.

2. Apr 20

   Leadership change

   24h Move

   -2.3%

   Appointment of new Chief Legal Officer succeeding long-tenured predecessor.

3. Apr 16

   Earnings scheduling

   24h Move

   -0.3%

   Announcement of Q1 2026 earnings release and webcast timing.

4. Apr 01

   Leadership change

   24h Move

   +2.0%

   Appointment of new Chief Medical Officer with broad development experience.

5. Mar 12

   Patient advocacy

   24h Move

   -5.5%

   Announcement of five recipients of 2026 Derek Forfang Patient Advocate Award.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

serum electrolytes, biomarkers, chronic kidney disease, phosphate absorption inhibitor, +4 more

8 terms

serum electrolytes medical

"impact of XPHOZAH® (tenapanor) on serum electrolytes and select nutrition biomarkers"

Serum electrolytes are measurements of key charged minerals in the liquid part of blood—mainly sodium, potassium, chloride and bicarbonate—that keep cells, nerves and the heart working properly. Like checking oil and battery levels in a car, abnormal electrolyte results can signal dehydration, kidney or heart problems, or drug side effects; they are common safety and diagnostic markers used in clinical trials and hospital care, so changes can influence regulatory outcomes, treatment use and a company’s financial prospects.

biomarkers medical

"impact of XPHOZAH® (tenapanor) on serum electrolytes and select nutrition biomarkers"

Biomarkers are measurable indicators found in the body, such as substances in blood or tissues, that reveal information about health or disease. For investors, they can signal how well a medical treatment is working or whether a disease is developing, helping to assess the potential success or risks of healthcare companies or innovations. Think of biomarkers as biological signals that provide clues about a person’s health status.

chronic kidney disease medical

"reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis"

Chronic kidney disease is a long-term, progressive loss of kidney function that reduces the organs’ ability to filter waste, control fluid levels and balance body salts. For investors, CKD matters because it creates sustained demand for tests, drugs, dialysis machines and transplants; advances in treatment or regulatory decisions can meaningfully change revenue prospects for companies—like a car that needs ongoing repairs, it creates predictable, long-term market needs.

phosphate absorption inhibitor medical

"XPHOZAH, the first and only phosphate absorption inhibitor (PAI), is approved"

A phosphate absorption inhibitor is a type of medicine that reduces the amount of dietary phosphorus the body takes in from the gut, acting like a sieve that prevents excess mineral from entering the bloodstream. Investors watch these drugs because they target a chronic condition common in kidney disease, so clinical trial results, regulatory approval, safety and ease of use can drive sales, market share and long‑term revenue potential.

hyperphosphatemia medical

"with Chronic Kidney Disease with Hyperphosphatemia on Dialysis"

An elevated level of phosphate in the blood, often caused by reduced kidney function or certain medications, that can harm bones, blood vessels and organs if untreated. Investors should care because prevalence, safety concerns and regulatory scrutiny around treatments or diagnostics for this condition can drive demand, affect clinical trial outcomes, influence healthcare spending and change a company’s revenue and risk profile—similar to how a common road hazard can change demand for safety products.

phosphate binders medical

"inadequate response to phosphate binders or who are intolerant of any dose"

Phosphate binders are medicines taken with food that block or trap dietary phosphate in the gut so it is not absorbed into the bloodstream, a key step for people whose kidneys cannot remove excess phosphate. They matter to investors because demand, pricing, regulatory approvals, and reimbursement for these drugs affect healthcare spending and the commercial prospects of companies that develop or sell them; think of them as a sponge that soaks up excess phosphate at mealtime.

mechanism of action medical

"The session will review the XPHOZAH mechanism of action, efficacy and safety data"

Mechanism of action describes how a drug, therapy, or medical product produces its effect in the body—the specific steps, targets, and biological processes it engages, like a key fitting into a lock to open a door. Investors care because a clear, well-understood mechanism reduces scientific uncertainty, supports regulatory approval and market confidence, and helps predict safety, effectiveness and additional uses, all of which influence a product’s commercial potential and a company’s valuation.

peer exchange technical

"Ardelyx is sponsoring a Peer Exchange, titled “Treating Hyperphosphatemia"

A peer exchange is a trading venue where orders are matched directly among participating firms or investors rather than routed through a fully public order book; think of it as a private marketplace where buyers and sellers trade with one another. It matters to investors because these venues can offer different prices, lower visible volume and faster execution, which affects liquidity, the cost of buying or selling shares, and how transparent those trades appear to the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Presentation evaluates the long-term impact of XPHOZAH® on serum electrolytes and select nutrition biomarkers

WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced an abstract accepted for poster presentation, sharing data on the long-term impact of XPHOZAH® (tenapanor) on serum electrolytes and select nutrition biomarkers, at the National Kidney Foundation’s (NKF) Spring Clinical Meetings, to be held May 7-10, 2026, in New Orleans.

XPHOZAH, the first and only phosphate absorption inhibitor (PAI), is approved by the U.S. Food and Drug Administration to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. XPHOZAH offers a different mechanism of action that blocks phosphate absorption at the primary pathway and is administered as a single tablet taken twice daily.

Information regarding NKF Spring Clinical Meetings, including the presentation abstract, can be found here.

Tenapanor Decreases Serum Phosphate Without Altering Other Serum Electrolytes in Patients with Chronic Kidney Disease with Hyperphosphatemia on Dialysis
Authors: Pablo E. Pergola, Yang Yang, Suling Zhao, Elizabeth Stremke, Susan Edelstein, David M. Spiegel
Poster: G-353
Display time: May 7, 2026, 5:15 - 7:30 PM CT

In addition to the poster presentation during NKF Spring Clinical Meetings, Ardelyx is sponsoring a Peer Exchange, titled “Treating Hyperphosphatemia and Side Effect Management,” on May 8 at 12:15 PM CT, where Lisa Gutekunst, MSEd, RD, CSR, CDN, will facilitate a peer exchange session discussing first-in-class PAI XPHOZAH. The session will review the XPHOZAH mechanism of action, efficacy and safety data, and practical considerations for XPHOZAH as add-on therapy for the many dialysis patients on a phosphate binder with serum phosphorus levels above guideline-established targets.

About XPHOZAH® (tenapanor)
XPHOZAH, discovered and developed by Ardelyx, is a first-in-class, phosphate absorption inhibitor with a differentiated mechanism of action that acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3), thereby reducing phosphate absorption through the paracellular pathway, the primary pathway of phosphate absorption. XPHOZAH is a single tablet, taken twice daily. Diarrhea was the most common side effect experienced by patients taking XPHOZAH in clinical trials. Please see additional full Prescribing Information.

About Hyperphosphatemia
Hyperphosphatemia is a serious condition, defined as elevated levels of phosphate in the blood, which affects the vast majority of the 550,000 patients in the United States with chronic kidney disease (CKD) on maintenance dialysis. The kidneys are responsible for eliminating excess phosphate and as kidney function declines, phosphate is not adequately eliminated from the body. As a result, hyperphosphatemia is a nearly universal condition among people with CKD on maintenance dialysis, with internationally recognized KDIGO treatment guidelines that recommend lowering elevated phosphate levels toward the normal range (2.5-4.5mg/dL).

IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
XPHOZAH is contraindicated in:

• Pediatric patients under 6 years of age
• Patients with known or suspected mechanical gastrointestinal obstruction

WARNINGS AND PRECAUTIONS
Diarrhea
Patients may experience severe diarrhea. Treatment with XPHOZAH should be discontinued in patients who develop severe diarrhea.

MOST COMMON ADVERSE REACTIONS
Diarrhea, which occurred in 43-53% of patients, was the only adverse reaction reported in at least 5% of XPHOZAH-treated patients with CKD on dialysis across trials. The majority of diarrhea events in the XPHOZAH-treated patients were reported to be mild-to-moderate in severity and resolved over time, or with dose reduction. Diarrhea was typically reported soon after initiation but could occur at any time during treatment with XPHOZAH. Severe diarrhea was reported in 5% of XPHOZAH-treated patients in these trials.

INDICATION
XPHOZAH (tenapanor), 30 mg BID, is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

For additional safety information, please see full Prescribing Information.

About Ardelyx

Ardelyx is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). The company’s pipeline includes the Phase 3 development of IBSRELA for chronic idiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx works with its partners to develop and commercialize its products outside of the United States. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.

Investor Contact:
Lisa Caperelli
SVP, Investor Relations & Corporate Communications
lcaperelli@ardelyx.com

Media Contact:
Lindsey Manuel
Associate Director, Corporate Communications
lmanuel@ardelyx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will Ardelyx present about XPHOZAH (ARDX) at the NKF Spring Clinical Meetings on May 7, 2026?

Ardelyx will present a poster on long-term effects of XPHOZAH on serum electrolytes and select nutrition biomarkers. According to Ardelyx, the poster evaluates tenapanor's impact in dialysis patients with hyperphosphatemia and is listed as Poster G-353 for May 7, 2026.

When and where is the XPHOZAH poster (ARDX) scheduled to be displayed at NKF Spring Clinical Meetings?

The XPHOZAH poster (G-353) is scheduled May 7, 2026, 5:15-7:30 PM CT in New Orleans. According to Ardelyx, the presentation is part of the NKF Spring Clinical Meetings taking place May 7-10, 2026.

What is the scope of the Peer Exchange Ardelyx (ARDX) is sponsoring at NKF on May 8, 2026?

Ardelyx is sponsoring a Peer Exchange titled “Treating Hyperphosphatemia and Side Effect Management” on May 8 at 12:15 PM CT. According to Ardelyx, the session will review XPHOZAH mechanism, efficacy, safety, and practical add-on therapy considerations.

What patient population does the ARDX poster focus on regarding tenapanor (XPHOZAH)?

The poster focuses on adults with chronic kidney disease on dialysis who have hyperphosphatemia and inadequate response or intolerance to phosphate binders. According to Ardelyx, the analysis examines serum electrolytes and select nutrition biomarkers in this population.

Does Ardelyx claim XPHOZAH changes serum electrolytes besides phosphorus in the presented data?

The headline finding indicates tenapanor decreases serum phosphate without altering other serum electrolytes in the studied dialysis patients. According to Ardelyx, the poster title summarizes this specific long-term observation for the trial population.

How can clinicians access the XPHOZAH abstract and presentation details for ARDX at NKF 2026?

Clinicians can find NKF Spring Clinical Meetings information and the presentation abstract through the NKF meeting resources. According to Ardelyx, the abstract and session details are available alongside the conference schedule for May 7-10, 2026.